Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mohamed A. Tantawy, Sameerah Shaheen, Shahad W. Kattan, Walla Alelwani, Ibrahim O. Barnawi, Gamal A. Elmgeed & Mohamed S. Nafie. (2022) Cytotoxicity, in silico predictions and molecular studies for androstane heterocycle compounds revealed potential antitumor agent against lung cancer cells. Journal of Biomolecular Structure and Dynamics 40:10, pages 4352-4365.
Read now
Read now
Kashif Haider, Shaik Rahaman, M Shahar Yar & Ahmed Kamal. (2019) Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018). Expert Opinion on Therapeutic Patents 29:8, pages 623-641.
Read now
Read now
Marco Tagliamento, Carlo Genova, Giovanni Rossi, Simona Coco, Erika Rijavec, Maria Giovanna Dal Bello, Simona Boccardo, Francesco Grossi & Angela Alama. (2019) Microtubule-targeting agents in the treatment of non-small cell lung cancer:
insights on new combination strategies and investigational compounds. Expert Opinion on Investigational Drugs 28:6, pages 513-523.
Read now
Read now
C Hardin, E Shum, AP Singh, R Perez-Soler & H Cheng. (2017) Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. Expert Opinion on Pharmacotherapy 18:7, pages 701-716.
Read now
Read now
Ziqing Duan, Cuitian Chen, Jing Qin, Qi Liu, Qi Wang, Xinchun Xu & Jianxin Wang. (2017) Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer. Drug Delivery 24:1, pages 752-764.
Read now
Read now
Articles from other publishers (14)
Sisi Zhang, Min Mo, Mengfan Lv, Wen Xia, Kun Liu, Gang Yu, Jia Yu, Guangcan Xu, Xiaoping Zeng, Sha Cheng, Bixue Xu, Heng Luo & Xueling Meng. (2023) Design, synthesis and bioevaluation of novel trifluoromethylquinoline derivatives as tubulin polymerization inhibitors. Future Medicinal Chemistry 15:21, pages 1967-1986.
Crossref
Crossref
Haoxiang Weng, Jinlong Li, Huajian Zhu, Kei Fung Carver Wong, Zheying Zhu & Jinyi Xu. (2023) An update on the recent advances and discovery of novel tubulin colchicine binding inhibitors. Future Medicinal Chemistry 15:1, pages 73-95.
Crossref
Crossref
Tingting Liang, Lu Lu, Xueting Song, Jianguo Qi & Jianhong Wang. (2022) Combination of microtubule targeting agents with other antineoplastics for cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188777.
Crossref
Crossref
Nadia Hanafy Metwally, Mohamed Ahmed Badawy & Doha Samir Okpy. (2022) Synthesis, biological evaluation of novel thiopyrano[2,3-d]thiazoles incorporating arylsulfonate moiety as potential inhibitors of tubulin polymerization, and molecular modeling studies. Journal of Molecular Structure 1258, pages 132648.
Crossref
Crossref
Wenxiao Jiang, Guiqing Cai, Peter Hu & Yue Wang. (2021) Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer. Acta Pharmaceutica Sinica B 11:11, pages 3406-3416.
Crossref
Crossref
Huanxi Wang, Xizi Jiang, Yu Cheng, Hongjiu Ren, Yujiao Hu, Yao Zhang, Hongbo Su, Zifang Zou, Qiongzi Wang, Zongang Liu, Jiameng Zhang & Xueshan Qiu. (2021) MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain. Cancer Science 112:6, pages 2210-2222.
Crossref
Crossref
Alessandra Benassi, Filippo Doria & Valentina Pirota. (2020) Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds. International Journal of Molecular Sciences 21:22, pages 8692.
Crossref
Crossref
Kousuke TamuraMakoto OnoTakefumi KawabeMotomu OharaEtsuo Yonemochi. (2020) Degradation Pathway of a Taxane Derivative DS80100717 Drug Substance and Drug Product. Chemical and Pharmaceutical Bulletin 68:4, pages 392-397.
Crossref
Crossref
Joan Cao, Zhou Zhu, Hui Wang, Timothy C. Nichols, Goldie Y. L. Lui, Shibing Deng, Paul A. Rejto, Todd VanArsdale, James S. Hardwick, Scott L. Weinrich & Ping Wei. (2019) Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. Oncogene 38:21, pages 4125-4141.
Crossref
Crossref
Pauline Gilson, Fernando Josa-Prado, Claire Beauvineau, Delphine Naud-Martin, Laetitia Vanwonterghem, Florence Mahuteau-Betzer, Alexis Moreno, Pierre Falson, Laurence Lafanechère, Véronique Frachet, Jean-Luc Coll, Jose Fernando Díaz, Amandine Hurbin & Benoit Busser. (2017) Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties. Scientific Reports 7:1.
Crossref
Crossref
Zhaoshi Bai, Meiqi Gao, Huijuan Zhang, Qi Guan, Jingwen Xu, Yao Li, Huan Qi, Zhengqiang Li, Daiying Zuo, Weige Zhang & Yingliang Wu. (2017) BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe. Cancer Letters 402, pages 81-92.
Crossref
Crossref
Pedro Morales-Ramírez, Teresita Vallarino-Kelly & Virginia Cruz-Vallejo. (2017) Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine. Cancer Chemotherapy and Pharmacology 79:5, pages 843-853.
Crossref
Crossref
Qile Xu, Yueting Wang, Jingwen Xu, Maolin Sun, Haiqiu Tian, Daiying Zuo, Qi Guan, Kai Bao, Yingliang Wu & Weige Zhang. (2016)
Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-
b
] Pyridazines as Antitubulin Agents
. ACS Medicinal Chemistry Letters 7:12, pages 1202-1206.
Crossref
Crossref
Labros G. Meimetis, Randy J. Giedt, Hannes Mikula, Jonathan C. Carlson, Rainer H. Kohler, David B. Pirovich & Ralph Weissleder. (2016) Fluorescent vinblastine probes for live cell imaging. Chemical Communications 52:64, pages 9953-9956.
Crossref
Crossref